Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

BACKGROUND: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals....

Descripción completa

Detalles Bibliográficos
Autores principales: Yulug, Burak, Altay, Ozlem, Li, Xiangyu, Hanoglu, Lutfu, Cankaya, Seyda, Lam, Simon, Velioglu, Halil Aziz, Yang, Hong, Coskun, Ebru, Idil, Ezgi, Nogaylar, Rahim, Ozsimsek, Ahmet, Bayram, Cemil, Bolat, Ismail, Oner, Sena, Tozlu, Ozlem Ozdemir, Arslan, Mehmet Enes, Hacimuftuoglu, Ahmet, Yildirim, Serkan, Arif, Muhammad, Shoaie, Saeed, Zhang, Cheng, Nielsen, Jens, Turkez, Hasan, Borén, Jan, Uhlén, Mathias, Mardinoglu, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879258/
https://www.ncbi.nlm.nih.gov/pubmed/36703196
http://dx.doi.org/10.1186/s40035-023-00336-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879258/
https://www.ncbi.nlm.nih.gov/pubmed/36703196
http://dx.doi.org/10.1186/s40035-023-00336-2

Ejemplares similares